Transketolase drives the development of aortic dissection by impairing mitochondrial bioenergetics

Chaoyun Wang,Li Zhang,Qinghua Zhang,Hui Zheng,Xi Yang,Weixing Cai,Qiuying Zou,Jingjing Lin,Lin Zhang,Lin Zhong,Xinyao Li,Yuqing Liao,Qin Liu,Liangwan Chen,Yumei Li
DOI: https://doi.org/10.1111/apha.14113
IF: 7.523
2024-02-23
Acta Physiologica
Abstract:Aim Aortic dissection (AD) is a disease with rapid onset but with no effective therapeutic drugs yet. Previous studies have suggested that glucose metabolism plays a critical role in the progression of AD. Transketolase (TKT) is an essential bridge between glycolysis and the pentose phosphate pathway. However, its role in the development of AD has not yet been elucidated. In this study, we aimed to explore the role of TKT in AD. Methods We collected AD patients' aortic tissues and used high‐throughput proteome sequencing to analyze the main factors influencing AD development. We generated an AD model using BAPN in combination with angiotensin II (Ang II) and pharmacological inhibitors to reduce TKT expression. The effects of TKT and its downstream mediators on AD were elucidated using human aortic vascular smooth muscle cells (HAVSMCs). Results We found that glucose metabolism plays an important role in the development of AD and that TKT is upregulated in patients with AD. Western blot and immunohistochemistry confirmed that TKT expression was upregulated in mice with AD. Reduced TKT expression attenuated AD incidence and mortality, maintained the structural integrity of the aorta, aligned elastic fibers, and reduced collagen deposition. Mechanistically, TKT was positively associated with impaired mitochondrial bioenergetics by upregulating AKT/MDM2 expression, ultimately contributing to NDUFS1 downregulation. Conclusion Our results provide new insights into the role of TKT in mitochondrial bioenergetics and AD progression. These findings provide new intervention options for the treatment of AD.
physiology
What problem does this paper attempt to address?